Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 1702 (LINC01702) is classified as a long intergenic non-coding RNA (lincRNA) gene in humans[1]. LincRNAs are a subclass of long non-coding RNAs longer than 200 nucleotides that do not overlap protein-coding genes. They are transcribed but not translated and have been shown to play diverse roles in regulating gene expression, chromatin remodeling, and genome architecture, sometimes acting through sequence-dependent or sequence-independent mechanisms[3][5]. Genome-wide studies suggest that lincRNAs often exhibit tissue-specific expression and may impact cellular functions or disease processes such as cancer or cell differentiation, though many lincRNAs (including LINC01702) remain insufficiently characterized in terms of direct biological roles, molecular interactions, or clinical relevance[1][3][5]. LINC01702 is not reported as a classical therapeutic target, and no drugs, mechanisms of action, or biomarker status have been documented.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 1702 (LINC01702).